4-氧代-哌啶-1,3-二羧酸苄基乙酯 | 154548-45-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氧代-哌啶-1,3-二羧酸苄基乙酯
• 中文别名: 1-N-CBZ-4-氧代-3-哌啶羧酸乙酯；N-CBZ-3-乙氧羰基-4-哌啶酮
• 英文名称: 1-benzyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate
• 英文别名: 1-O-benzyl 3-O-ethyl 4-oxopiperidine-1,3-dicarboxylate
• CAS: 154548-45-5
• 化学式: C₁₆H₁₉NO₅
• 分子量: 305.331
• InChiKey: DYBIHRBNPRCTAS-UHFFFAOYSA-N

物化性质

• 沸点：
  446.4±45.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Oxo-piperidine-1,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Oxo-piperidine-1,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester
CAS number: 154548-45-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H19NO5
Molecular weight: 305.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氧代-哌啶-1,3-二羧酸苄基乙酯 在 盐酸 、 trichloromethyl silane 、 sodium cyanoborohydride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 反应 61.5h， 生成 1-formic acid-3-benzyloxycarbonyl-7-benzyl-3,7-diazabicyclo[3,3,1]nonane
  参考文献：
  名称：

  1,3,7-三取代-3,7-二氮杂双环[3,3,1]壬烷衍生物 及制备方法

  摘要：

  本发明涉及1,3,7-三取代-3,7-二氮杂双环[3,3,1]壬烷取代衍生物及制备方法，主要解决目前的3,7-二氮杂双环[3,3,1]壬烷结构的桥环化合物在空间结构延伸受到限制不利于快速筛选化合物活性以及进行SAR分析的技术问题。化学结构式如下：，其中R1为取代官能团或氨基的保护基，选自H或苄基；R2为取代官能团或氨基的保护基，选自H或苄氧羰基；G为羟甲基、羧基、酯基、甲酰胺基的一种。

  公开号：

  CN102875550B
• 作为产物：
  描述：

  氯甲酸苄酯 在 palladium dihydroxide 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、275.8 kPa 条件下， 反应 15.0h， 以78%的产率得到4-氧代-哌啶-1,3-二羧酸苄基乙酯
  参考文献：
  名称：

  [EN] PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES
  [FR] DERIVES DE PYRAZOLE EN TANT QU'INHIBITEURS DE RECEPTEUR TYROSINE KINASES

  摘要：

  化合物的化学式（I）及其在抑制Trk活性中的应用被描述。

  公开号：

  WO2005049033A1

文献信息

• [EN] 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS<br/>[FR] COMPOSÉS 2-HÉTÉROCYCLYLAMINO PYRAZINES SUBSTITUÉES EN POSITION 6 EN TANT QU'INHIBITEURS DE CHK-1
  申请人：PFIZER

  公开号：WO2010016005A1

  公开（公告）日：2010-02-11

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

  本发明涉及式(I)的化合物，及其药用可接受的盐，它们的合成以及它们作为CHK-1抑制剂的用途。
• Immunopotentiator agents
  申请人：Eli Lilly and Company

  公开号：US06664271B1

  公开（公告）日：2003-12-16

  Novel compounds and methods for preparing same, immunopotentiating compositions, and a method for potentiating the immune system of a host animal. The method comprises administering to the animal an effective amount of an immunopotentiating compound of Formula I or Formula II, or a physiologically acceptable salt.

  新化合物和制备方法，免疫增强组合物，以及增强宿主动物免疫系统的方法。该方法包括向动物施用公式I或公式II的免疫增强化合物或生理上可接受的盐的有效量。
• Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations
  作者：Yong Zhang、Kai Zhang、Meng Zhao、Lixia Zhang、Mingze Qin、Shuchun Guo、Yanfang Zhao、Ping Gong

  DOI：10.1016/j.bmc.2015.05.059

  日期：2015.8

  13c, 13n, 13o, 13p, 13r, 13s, 13u and 24c obviously. By evaluation of inhibiting EGFR and HER2 kinases, seven compounds (13b, 13g, 13n, 13o, 13p, 13r and 13s) showed stronger EGFR potency with IC50 ⩽ 18 nM, which could also be understood by preliminary docking study of 13b with EGFR kinase. In view of the primary SAR, bisarylaniline derivatives (13o, 13p, 13r and 13s) showed obvious improvements on

  设计，合成了一系列新颖的4-芳基氨基-6 / 7-取代的5,6,7,8-四氢吡啶并[4,3- d ]嘧啶类化合物，它们作为潜在的抗增殖剂和EGFR激酶抑制剂具有生物活性被评估。THPPs中的N-丙烯酰胺片段和带有取代基的4-苯胺基团都起着关键作用，因为它们对四种癌细胞系（HT29，A549，H460和H1975）具有显着的抗增殖活性。吉非替尼抗性的H1975尤其抑制活性显示更有利的，这可从化合物可以观察到图13B，13C，13N，13O，13P，13R，13S，13u和24c显然。通过抑制EGFR和HER2激酶，七种化合物（评价13B，13克，13N，13O，13P，13R和13S）显示更强的EGFR效力与IC 50  ⩽18纳米，这也可以通过初步对接研究理解13b中与EGFR激酶。鉴于原发性SAR，双芳基苯胺衍生物（13o，13p，13r和13s）显示出对HER2抑制的明显改善，表明它们是潜在的EGFR
• Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-<i>d</i> ]pyrimidine-6(5<i>H</i> )-carboxylate derivatives as potential EGFR inhibitors
  作者：Dajun Zhang、Yan Yan、Ge Jin、Bo Liu、Xiaoliang Ma、Dan Han、Xiaojian Jia

  DOI：10.1002/ardp.201800110

  日期：2018.9

  factor receptor (EGFR), HER2, and VEGFR identified compound 5a as a promising hit that exhibited considerable potency both in cellular (IC50 = 5.67, 17.04, 11.29, and 12.65 µM, respectively) and EGFR enzymatic assays (IC50 = 14.8 nM). Compound 5a was capable of down‐regulating the expression of EGFR and inhibited EGFR phosphorylation in a dose‐dependent manner, representing a potential EGFR candidate for

  合成了新系列的 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylates (5a-p, 7, and 8a-e) 并评估了它们对 A549 的抗增殖活性、HT29、H460 和 H1975 癌细胞系体外。九种化合物（5a–c、5i、5j、7、8a、8b、8i）在 A549 细胞上表现出中等到显着的细胞毒活性，IC50 值低于 18 µM，与参考吉非替尼的 IC50 值相当（IC50 = 18.44 µM） . 特别是，对表皮生长因子受体 (EGFR)、HER2 和 VEGFR 的进一步酶促分析确定化合物 5a 是一种很有前景的命中物，在细胞（IC50 分别为 5.67、17.04、11.29 和 12.65 µM）和 EGFR 中均表现出相当大的效力酶促测定 (IC50 = 14.8 nM)。
• Triazine Derivatives
  申请人：Pfizer Inc.

  公开号：US20140329820A1

  公开（公告）日：2014-11-06

  The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R 1 , R 2 , R 3 , and R 4 are as defined herein and to the use of the compounds as PDE10 inhibitors.

  本发明涉及一种新的三嗪衍生物类别，如下式所示，其中A、X、R1、R2、R3和R4如本文所定义，并且涉及将这些化合物用作PDE10抑制剂。